Ascendis Pharma ADR

  • TickerASND
  • ISINUS04351P1012
  • ExchangeNASDAQ Stock Market
  • SectorPharmaceuticals & Biotechnology
  • CountryDenmark
Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

Liana Moussatos ...
  • Shveta Dighe

Strong Cash Position; TC-hGH Receives Positive Opinion from EMA PDCO for PIP

Dave Nicoski ...
  • Ross LaDuke

Vermilion Short Shots: Technically Vulnerable Stocks

Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.

Dave Nicoski ...
  • John Betz

Vermilion Compass: Weekly Equity Strategy

• Bullish but selective. As we alluded to last week, our long-term bullish outlook remains intact. However, looking through the charts we find a growing list of extended and parabolic patterns. While we continue to remain bullish, we acknowledge the likelihood of backing and filling, or a pause, is building. The further a stock's price action moves from its 200-day, the greater the possibility of a corrective reversion to the mean, or pullback. In last week's Compass our example was Boeing Corporation (BA). The stock is trading 40% above its 200-day moving average, and this rate of momentum i...

Wedbush Research

Wedbush Morning Call - Jul 13 2020 6:44AM

Liana Moussatos ...
  • Shveta Dighe

Strong Cash Position; TC-hGH Receives Positive Opinion from EMA PDCO for PIP

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

Wedbush Research

Wedbush Morning Call - Jun 29 2020 6:40AM

Ashiq Mubarack ...
  • David Nierengarten
  • Jeffrey La Rosa
  • Kenneth Shields
  • Laura Chico
  • Liana Moussatos
  • Matthew Barcus
  • Robert Driscoll
  • Shveta Dighe

The Week Ahead in Life Sciences

ASCENDIS PHARMA reduced its risk exposure resulting in an upgrade to Slightly Positive

ASCENDIS PHARMA (US), a company active in the Biotechnology industry, reduced its market risk and raised its general evaluation. The independent financial analyst theScreener awarded an improved star rating to the company, which now shows 2 out of 4 possible stars; its market behaviour has improved and can be considered as defensive. theScreener believes that this new assessment merits an overall rating upgrade to Slightly Positive. As of the analysis date June 19, 2020, the closing price was USD 146.07 and its potential was estimated at USD 164.17.

ResearchPool Subscriptions

Get the most out of your insights

Get in touch